Rituximab in thrombotic primary antiphospholipid syndrome: a pilot study from a single centre in China.

导出 LinkOut

翻译打印收藏纠错

作者： Yijun,You ^[1] ; Ce,Shi ^[2] ; Zhuochao,Zhou ^[1] ; Fan,Wang ^[1] ; Yue,Sun ^[1] ; Jialin,Teng ^[1] ; Honglei,Liu ^[1] ; Xiaobing,Cheng ^[1] ; Yutong,Su ^[1] ; Hui,Shi ^[1] ; Chengde,Yang ^[3] ; Junna,Ye ^[3]

作者单位： Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ^[1] Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ^[2] Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China yjn0912@qq.com yangchengde@sina.com. ^[3]

关键词 antibodies antiphospholipid antiphospholipid syndrome rituximab

主题词抗体, 抗磷脂(Antibodies, Antiphospholipid);抗磷脂综合征(Antiphospholipid Syndrome);人类(Humans);试点项目(Pilot Projects);血栓形成(Thrombosis)

DOI 10.1136/annrheumdis-2020-219303

PMID 33452001

发布时间 2022-07-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交